Clinical Trials: US FDA Should Frame Risk-Based Monitoring As Best Practice, ACRO Says

Recent Q&A draft guidance is aimed at assisting sponsors in planning and conducting risk-based approaches to monitoring, but ACRO’s Doug Peddicord says agency needs to take a more straightforward, proactive approach to encouraging the move away from 100% source data verification.